Edwards Lifesciences Corp
EW: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$59.00 | Jngbqw | Bqxdfdvbq |
Edwards Sees Tepid TAVR Growth Thanks to Hospital Labor Issues
Business Strategy and Outlook
Over the last two decades, Edwards Lifesciences has demonstrated that it knows how to maintain leadership through innovation of tissue heart valves. Edwards remains the dominant force in surgical heart valves and minimally invasive valve therapy—one of the hottest areas in cardiac devices.